Basic Information
| Drug ID | DDPD00799 |
|
| Drug Name | Tazarotene | |
| Molecular Weight | 351.462 | |
| Molecular Formula | C21H21NO2S | |
| CAS Number | 118292-40-3 | |
| SMILES | CCOC(=O)C1=CN=C(C=C1)C#CC1=CC2=C(SCCC2(C)C)C=C1 | |
| External Links | ||
| DRUGBANK | DB00799 | |
| PubChem Compound | 5381 | |
| PDR | 1116 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 5.6 | - | 5.6 | - | DRUGBANK |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| Clearance | 2.2 | L/h/kg | 37.2 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 3.6 | L/kg | 3.55 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 18.0 | h | ~18 | h | normal,healthy; patients; | DRUGBANK | Half-life | 18.0 | h | ~18 | h | hyperthyroid; patients; | DRUGBANK | Half-life | 6.2 | h | 6.22 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Protein Binding | 99.0 | % | >99 | % | plasma proteins; | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Frequency | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|---|
| Max dose for children | 1.0 | application/day | 1 | application/day | skin/dermal | qd | Avage | tazarotene | PDR |
| Max dose for children | 1.0 | application/day | 1 | application/day | skin/dermal | qd | Avage | tazarotene | PDR |
| Max dose for adolescents | 1.0 | application/day | 1 | application/day | skin/dermal | qd | Avage | tazarotene | PDR |
| Max dose for adolescents | 1.0 | application/day | 1 | application/day | skin/dermal | qd | Avage | tazarotene | PDR |
| Max dose for adults | 1.0 | appLication/day | 1 | appLication/day | skin/dermal | qd | Avage | tazarotene | PDR |
| Max dose for geriatric | 1.0 | application/day | 1 | application/day | skin/dermal | qd | Avage | tazarotene | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1